Clinical trials: Rectal Cancer Stage IV
Colorectal Cancer
Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003287
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- 36 sites in Austria, Belgium and 7 more
- Volunteers
- 554 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life.
- Conditions
- Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8
- Trial name
- NCT06265285
- Testing
- Home Health Encounter, Nivolumab, Patient Monitoring
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Colorectal Cancer Stage IV
Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
The investigators hypothesize that intermittent first-line Panitumumab plus FOLFIRI is effective in first line as the same regimen given continuously, resulting in a Time to Treatment Failure (TTF) not inferior to that obtained…
- Trial name
- IMPROVE-2 (NCT06509126)
- Testing
- Panitumumab, Irinotecan, 5-fluorouracil
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- National Cancer Institute, Naples
Colorectal Cancer, Metastatic Cancer
Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer
RATIONALE: Embolization blocks blood flow to part of an organ and/or tumor. Blocking the portal vein on one side of the liver may cause the opposite side of the liver to increase in size and decrease the risk of liver failure…
- Trial name
- NCT00028626
- Testing
- embolization therapy
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma
Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer
This phase II trial studies the side effects and how well niraparib and panitumumab work in treating patients with colorectal cancer that has spread to other places in the body.
- Conditions
- Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Microsatellite Stable, RAS Wild Type
- Trial name
- NIPAVect (NCT03983993)
- Testing
- Niraparib, Panitumumab
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Emory University
Anal Cancer Stage III A, Anal Cancer Stage III B
Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus
The CORINTH trial is for patients with more advanced (stage 3 and 4) anal cancer. The numbers of patients with anal cancer is increasing and only 65% patients with this later stage anal cancer have not had a recurrence 3 years…
- Trial name
- CORINTH (NCT04046133)
- Testing
- Pembrolizumab
- Where
- 11 sites in Norway, United Kingdom
- Volunteers
- 52 people
- Sponsor
- Cardiff University
Solid Organ Cancers
GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers
The purpose of this study is to evaluate the safety of the investigational product GL-ONC1. GL-ONC1, a vaccinia virus, has been genetically modified for use as a potential anti-cancer drug to destroy cancer cells.
- Trial name
- NCT02714374
- Testing
- GL-ONC1
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Andrew Lowy
Locally Advanced Rectal Cancer (LARC), Mismatch Repair-Proficient (pMMR) Rectal Cancer
QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer
This is a multicenter, prospective, phase II study evaluating total neoadjuvant therapy (TNT) consisting of short-course radiotherapy (SCRT; 5×5 Gy) followed by QL1706 (a bifunctional MabPair antibody targeting PD-1 and CTLA-4…
- Conditions
- Locally Advanced Rectal Cancer (LARC), Mismatch Repair-Proficient (pMMR) Rectal Cancer, Non-metastatic Rectal Cancer
- Trial name
- NCT07175636
- Testing
- Drug: QL1706 Drug: mFOLFOX6 Radiation: Short-Course Radiotherapy (SCRT)
- Volunteers
- 66 people
- Sponsor
- Sun Yat-sen University
NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
This is a multicenter, open-label, randomized (1:1) trial designed to evaluate whether ctDNA-guided interruption of immune-checkpoint inhibitor (ICI) therapy provides comparable survival to standard of care (SoC) continuous ICI…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLC
- Trial name
- SIGNAL-IO 301 (NCT07689812)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 920 people
- Sponsor
- Natera, Inc.
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery…
- Conditions
- Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
- Trial name
- LOTUS (NCT06073431)
- Testing
- Biospecimen Collection, Computed Tomography, Electronic Health Record Review
- Where
- 225 sites in United States
- Volunteers
- 800 people
- Sponsor
- University of Rochester
Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma
Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of trametinib and trifluridine and tipiracil hydrochloride in treating patients with colon or rectal cancer that has spread to other places in the body…
- Conditions
- Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Carcinoma, RAS Family Gene Mutation
- Trial name
- NCT03317119
- Testing
- Laboratory Biomarker Analysis, Trametinib, Trifluridine and Tipiracil Hydrochloride
- Where
- 8 sites in United States
- Volunteers
- 26 people
- Sponsor
- City of Hope Medical Center
Colorectal Cancer
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00006046
- Testing
- monoclonal antibody hu3S193
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Ludwig Institute for Cancer Research
Rectal Adenocarcinoma
ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
The purpose of this study is to see how effective and safe LY2157299, in combination with chemotherapy and radiation therapy, might be in treating rectal cancer.
- Trial name
- NCT02688712
- Testing
- LY2157299, Capecitabine, Fluorouracil
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Providence Health & Services
Colorectal Carcinoma, CRC
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
The purpose of this study is to evaluate the safety, tolerability, and efficacy of JX-594 (Pexa-Vec) administered intravenously either alone or in combination with Irinotecan in colorectal carcinoma patients who are refractory to…
- Trial name
- NCT01394939
- Testing
- JX-594, Irinotecan
- Where
- 11 sites in United States, Canada and 1 more
- Volunteers
- 52 people
- Sponsor
- Jennerex Biotherapeutics
Unresectable Metastatic Rectal Cancer, CAPOX
Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer
To evaluate the efficacy and safety of short-course radiotherapy followed by CAPOX and carrilizumab and bevacizumab or cetuximab in the initial treatment of unresectable metastatic rectal cancer
- Conditions
- Unresectable Metastatic Rectal Cancer, CAPOX, Combination of Radioimmunotherapy
- Trial name
- Union-mRC (NCT07059949)
- Testing
- CAPOX+ Camrelizumab+ Cetuximab, CAPOX+ Camrelizumab+ Bevacizumab
- Volunteers
- 80 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Colorectal Neoplasms, Colorectal Cancer (Diagnosis)
MRD Monitoring in Colorectal Cancer Using ctDNA
This clinical study evaluates the use of free circulating tumor DNA (ctDNA) analysis from peripheral blood, known as liquid biopsy.
- Conditions
- Colorectal Neoplasms, Colorectal Cancer (Diagnosis), Minimal Residual Disease
- Trial name
- RezidRAS (NCT07895459)
- Testing
- Blood draw for ctDNA analysis
- Where
- Czechia
- Volunteers
- 60 people
- Sponsor
- Masaryk Memorial Cancer Institute
Rectal Cancer, Non Metastatic Rectal Cancer
ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer
This prospective observational, non-therapeutic study for patients with T3, T4, or node positive rectal cancer eligible to undergo total neoadjuvant therapy.
- Trial name
- NCT05629442
- Testing
- ctDNA
- Sponsor
- Massachusetts General Hospital
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Colorectal Cancer, Metastatic Cancer
Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer
RATIONALE: Diagnostic procedures, such as lymphography, may improve the identification of patients with metastatic colorectal cancer.
- Trial name
- NCT00003186
- Testing
- isosulfan blue, lymphangiography, sentinel lymph node biopsy
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8
Collection of Blood, Urine, and Stool to Monitor MetastaticColorectal Cancers
This trial studies the monitoring of therapy and progression by collecting blood, urine, and stool from participants with colorectal cancer that has spread to other places in the body or cannot be removed by surgery.
- Conditions
- Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8
- Trial name
- NCT03563651
- Testing
- Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Southern California